Much of our interdisciplinary research focuses on the United Nations Sustainable Development Goals (SDGs) – 17 goals to create a better world by 2030, from ending poverty to addressing climate change.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

From December 1-4, our Women in Business Club went on a field trip to Boston. Thanks to Kelly Kimball, MBA Adjunct Professor, ...

Wilson Sonsini annually publishes the Silicon Valley 150 Corporate Governance Report, which analyzes the governance practices and disclosures of ...

AD is a progressive, relentless disease with Aß and tau as hallmarks. It is caused by a continuous underlying neurotoxic process driven by PF that begins before amyloid plaque accumulation and ...

Cairo, Egypt — Standard Chartered, AUC Venture Lab, and Village Capital announced the successful completion of the first ...

The EMBA in Austria has recruited several students for a scholarship to be a part of the new cohort. Hub101 opened the ...

The UK and Overseas Territories issued a Joint Communiqué following the 2025 Joint Ministerial Council Meetings in ...

KATHMANDU, Nov 29: The 16th meeting of the EU-Nepal Joint Commission meeting concluded in Brussels of Belgium on Friday.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA ...